Scarica l'app Stockscreener
28.56
3.02%
-0.89
Dopo l'orario di chiusura:
28.56
Precedente Chiudi:
$29.45
Aprire:
$28.12
Volume 24 ore:
243.62K
Relative Volume:
1.45
Capitalizzazione di mercato:
$1.86B
Reddito:
-
Utile/perdita netta:
$-180.80M
Rapporto P/E:
-8.8765
EPS:
-3.2175
Flusso di cassa netto:
$-150.76M
1 W Prestazione:
+4.27%
1M Prestazione:
+2.00%
6M Prestazione:
+23.21%
1 anno Prestazione:
+91.04%
Intervallo 1D:
$27.78
$28.82
Intervallo di 1 settimana:
$26.52
$29.85
Portata 52W:
$11.51
$29.85
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
28.56 | 1.86B | 0 | -180.80M | -150.76M | -3.2175 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-10-15 | Iniziato | H.C. Wainwright | Buy |
| 2025-10-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Iniziato | Guggenheim | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Iniziato | Wedbush | Outperform |
| 2023-08-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Iniziato | Bryan Garnier | Buy |
| 2022-09-13 | Ripresa | JMP Securities | Mkt Outperform |
| 2022-08-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-03-02 | Iniziato | BofA Securities | Neutral |
| 2021-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2021-03-02 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Pharvaris Nv Borsa (PHVS) Ultime notizie
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Published on: 2026-04-05 13:07:26 - baoquankhu1.vn
Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)? - simplywall.st
Pharvaris (PHVS) accounting officer has 1,164 shares withheld for RSU tax obligations - Stock Titan
Pharvaris (PHVS) CTO-level executive corrects Form 3/A to 49,216 shares - Stock Titan
Pharvaris NV expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Pharvaris N.V.Ordinary Shares (NQ: PHVS - The Chronicle-Journal
Pharvaris Q4 and Full Year 2025 Earnings: Net Loss Reaches €176M as Clinical Pipeline Advances - Bayelsa Watch
Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones - ChartMill
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data - TipRanks
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - bitget.com
Pharvaris Announces Completion of Enrollment in CHAPTER-3 Study of Deucrictibant XR for HAE Prophylaxis, with Topline Data Expected in 3Q2026 - Quiver Quantitative
Earnings Flash (PHVS) Pharvaris Posts Q4 Loss 0.72 Euro a Share - MarketScreener
PHVS: Phase 3 HAE study enrollment completed; NDA submission and strong liquidity position maintained - TradingView
Pharvaris (NASDAQ: PHVS) outlines HAE pipeline, capital needs and key risks - Stock Titan
Pharvaris (PHVS) deepens 2025 loss while pivotal HAE trials hit key milestones - Stock Titan
Pharvaris completes pivotal HAE study, data due in Q3 2026 - Stock Titan
Pharvaris (NASDAQ:PHVS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Does Pharvaris (PHVS) Have a Chance to Surge 59.93% According to Wall Street Analyst Predictions? - Bitget
Pharvaris NV (PHVS) price target increased by 20.90% to 45.73 - MSN
Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect? - sharewise.com
Trading Systems Reacting to (PHVS) Volatility - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) versus BioXcel Therapeutics (NASDAQ:BTAI) Critical Comparison - Defense World
Tudor Investment Corp ET AL Invests $1.94 Million in Pharvaris N.V. $PHVS - MarketBeat
Pharvaris N.V. (PHVS) Presents at 2026 Global Angioedema Leadership ConferenceSlideshow - seekingalpha.com
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeShould You Buy? - MarketBeat
PHVS.O Technical Analysis & Stock Price Forecast - Intellectia AI
PHVS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
How Pharvaris N.v. (PHVS) Affects Rotational Strategy Timing - Stock Traders Daily
Lancet publishes Phase 2 oral treatment data for rare swelling disorder - Stock Titan
Guggenheim maintains Pharvaris NV (PHVS) buy recommendation - msn.com
[Form 3] Pharvaris N.V. Initial Statement of Beneficial Ownership - Stock Titan
Pharvaris (PHVS) director Glassman reports stock options and RSU holdings - Stock Titan
Pharvaris (PHVS) director discloses sizable stock and option holdings - Stock Titan
Pharvaris (NASDAQ: PHVS) director details options, RSUs and shares - Stock Titan
Pharvaris (PHVS) CFO discloses common stock and option holdings - Stock Titan
Pharvaris (NASDAQ: PHVS) CTO reports option grants and share holdings - Stock Titan
Pharvaris (PHVS) CCO reports initial stock, RSU and option holdings - Stock Titan
Pharvaris (PHVS) PAO reports initial share, option and RSU holdings - Stock Titan
Pharvaris (PHVS) director David Meeker reports stock, options and RSUs - Stock Titan
Pharvaris (PHVS) director Viviane Monges details initial equity holdings - Stock Titan
Pharvaris (PHVS) CMO Lu Peng details initial share and stock option holdings - Stock Titan
Pharvaris (PHVS) CEO Berndt Modig details stock, RSUs and options - Stock Titan
Pharvaris (PHVS) CHRO details option and RSU equity holdings - Stock Titan
Is New HAE Patient-Reported Outcome Study Altering The Investment Case For Pharvaris’ Deucrictibant (PHVS)? - simplywall.st
Trend Recap: How sensitive is Pharvaris NV to inflation2026 Risk Factors & Long Hold Capital Preservation Tips - baoquankhu1.vn
Assessing Pharvaris (PHVS) Valuation After New Real‑World HAE Study Supports Deucrictibant Trials - Sahm
Patient attack ratings to guide Pharvaris hereditary angioedema trials - Stock Titan
PHVS: Oral therapies for angioedema show strong data, with launches and key filings expected by 2027 - TradingView
RBC Capital initiates coverage of Pharvaris NV (PHVS) with outperform recommendation - MSN
Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Royal Bank Of Canada - Defense World
Pharvaris Nv Azioni (PHVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):